Articles

Splice-Break finds key DNA deletions

A new approach to studying deletions in the mitochondria could inform disease study
Written byKristen Smith
| 4 min read

IRVINE, Calif.—Research originating at the University of California, Irvine (UCI) demonstrates the efficacy of a reliable, high-throughput technique to analyze mitochondrial DNA (mtDNA) and identify significant deletions that lead to disease. Building on an existing RNA-seq alignment algorithm, the team developed a process to be able to use it to detect and quantify mitochondrial deletions. Preliminary testing has indicated that significant deletion burdens are present in brain samples from patients with major depressive disorder, which may eventually lead to new psychiatric treatment possibilities.

Deletions in the 16.6 kb mitochondrial genome have been implicated in numerous disorders that often display muscular and/or neurological symptoms due to the high-energy demands of these tissues. Dr. Marquis Vawter in the Department of Psychiatry and Human Behavior at UCI has been exploring changes in mitochondrial DNA for several years. His team has worked to evaluate single nucleotide variants, rare point mutations and one of the known deletions in mitochondrial DNA, specifically looking in brain tissue of subjects with mental illnesses. Vawter challenged Dr. Brooke E. Hjelm, then the Della Martin Fellow in Psychiatric Genetics in his lab, to develop a computational approach to find large mitochondrial DNA deletions in the next-generation sequencing data.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.